- $135.55m
- $118.16m
- $27.47m
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:43 AM
NASDAQ RESUMED AT 09:40 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:30 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Cue Biopharma To Receive $7.5 Million Preclinical Milestone Payment From Boehringer Ingelheim Collaboration And License Agreement
Brief: Cue Biopharma Says Preclinical Milestone Triggers $7.5 Mln Payment Under Boehringer Deal
Brief: Cue Biopharma Inc - Lucinda Warren To Continue As Chief Financial And Business Officer - SEC Filing
Cue Biopharma Q4 revenue surges on ImmunoScape deal
Brief: Cue Biopharma Appoints Industry Veteran Lucinda Warren As Chief Financial And Business Officer
Brief: Cue Biopharma Announces Pricing Of $10 Million Public Offering
Brief: Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer Treatment
Cue Biopharma Q3 collaboration revenue falls
Brief: Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Brief: Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies
Cue Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cue Biopharma Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Cue Biopharma Updates on CUE-101 at DAVA 4th Hawaii Summit
Brief: Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO